Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 1592

1.

Mucosal Autoimmunity to Cell-Bound GP2 Isoforms Is a Sensitive Marker in PSC and Associated With the Clinical Phenotype.

Sowa M, Kolenda R, Baumgart DC, Pratschke J, Papp M, Tornai T, Suchanski J, Bogdanos DP, Mytilinaiou MG, Hammermann J, Laass MW, Conrad K, Schramm C, Franke A, Roggenbuck D, Schierack P.

Front Immunol. 2018 Aug 28;9:1959. doi: 10.3389/fimmu.2018.01959. eCollection 2018.

2.

PSC-IBD: specific phenotype of inflammatory bowel disease associated with primary sclerosing cholangitis.

Bajer L, Wohl P, Drastich P.

Vnitr Lek. 2018 Summer;64(6):659-664.

PMID:
30223664
3.

Primary sclerosing cholangitis in children versus adults: lessons for the clinic.

Adike A, Carey EJ, Lindor K.

Expert Rev Gastroenterol Hepatol. 2018 Sep 10. doi: 10.1080/17474124.2018.1521719. [Epub ahead of print]

PMID:
30199272
4.

Primary Sclerosing Cholangitis, Part 2: Cancer Risk, Prevention, and Surveillance.

Tabibian JH, Ali AH, Lindor KD.

Gastroenterol Hepatol (N Y). 2018 Jul;14(7):427-432.

5.

Chronic genotype 1 hepatitis E infection from immunosuppression for ileo-colonic Crohn's disease.

Robins AEM, Bowden DJ, Gelson WTH.

Oxf Med Case Reports. 2018 Aug 25;2018(9):omy059. doi: 10.1093/omcr/omy059. eCollection 2018 Sep.

6.

Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise?

Ma C, Kotze PG.

Aliment Pharmacol Ther. 2018 Sep;48(5):576-577. doi: 10.1111/apt.14858. No abstract available.

PMID:
30156325
7.

Gut and Liver B Cells of Common Clonal Origin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease.

Chung BK, Henriksen EKK, Jørgensen KK, Karlsen TH, Hirschfield GM, Liaskou E.

Hepatol Commun. 2018 Aug 6;2(8):956-967. doi: 10.1002/hep4.1200. eCollection 2018 Aug.

8.

Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease.

Belle A, Laurent V, Pouillon L, Baumann C, Orry X, Lopez A, Rousseau H, Bronowicki JP, Peyrin-Biroulet L.

Dig Liver Dis. 2018 Jul 31. pii: S1590-8658(18)30813-2. doi: 10.1016/j.dld.2018.06.024. [Epub ahead of print]

PMID:
30076016
9.

Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Buchholz BM, Lykoudis PM, Ravikumar R, Pollok JM, Fusai GK.

World J Gastroenterol. 2018 Jul 28;24(28):3171-3180. doi: 10.3748/wjg.v24.i28.3171.

10.

Oral vancomycin induces sustained deep remission in adult patients with ulcerative colitis and primary sclerosing cholangitis.

de Chambrun GP, Nachury M, Funakoshi N, Gerard R, Bismuth M, Valats JC, Panaro F, Navarro F, Desreumaux P, Pariente B, Blanc P.

Eur J Gastroenterol Hepatol. 2018 Oct;30(10):1247-1252. doi: 10.1097/MEG.0000000000001223.

PMID:
30052539
11.

Linking the gut and liver: crosstalk between regulatory T cells and mucosa-associated invariant T cells.

Atif M, Warner S, Oo YH.

Hepatol Int. 2018 Jul;12(4):305-314. doi: 10.1007/s12072-018-9882-x. Epub 2018 Jul 19. Review.

12.

How Does the Epidemiology of Inflammatory Bowel Disease Differ between East and West? A Korean Perspective.

Yang SK.

Inflamm Intest Dis. 2017 Nov;2(2):95-101. doi: 10.1159/000454712. Epub 2017 Jan 14. Review.

PMID:
30018960
13.

Primary Sclerosing Cholangitis, Part 1: Epidemiology, Etiopathogenesis, Clinical Features, and Treatment.

Tabibian JH, Ali AH, Lindor KD.

Gastroenterol Hepatol (N Y). 2018 May;14(5):293-304.

14.

Risk factors and clinical courses of concomitant primary sclerosing cholangitis and ulcerative colitis: a Korean multicenter study.

Park YE, Cheon JH, Park JJ, Kim YJ, Choi CH, Park Y, Park SJ, Kim TI, Kim WH.

Int J Colorectal Dis. 2018 Jul 9. doi: 10.1007/s00384-018-3123-6. [Epub ahead of print]

PMID:
29987360
15.

Malignancy and mortality in paediatric-onset inflammatory bowel disease: a 3-year prospective, multinational study from the paediatric IBD Porto group of ESPGHAN.

Joosse ME, Aardoom MA, Kemos P, Turner D, Wilson DC, Koletzko S, Martin-de-Carpi J, Fagerberg UL, Spray C, Tzivinikos C, Sladek M, Shaoul R, Roma-Giannikou E, Bronsky J, Serban DE, Ruemmele FM, Garnier-Lengline H, Veres G, Hojsak I, Kolho KL, Davies IH, Aloi M, Lionetti P, Hussey S, Veereman G, Braegger CP, Trindade E, Wewer AV, Hauer AC, de Vries ACH, Sigall Boneh R, Sarbagili Shabat C, Levine A, de Ridder L; Paediatric IBD Porto group of ESPGHAN.

Aliment Pharmacol Ther. 2018 Sep;48(5):523-537. doi: 10.1111/apt.14893. Epub 2018 Jul 8.

PMID:
29984520
16.

Corrigendum to Reviewing the Risk of Colorectal Cancer in Inflammatory Bowel Disease After Liver Transplantation for Primary Sclerosing Cholangitis.

[No authors listed]

Inflamm Bowel Dis. 2018 Jul 5. doi: 10.1093/ibd/izy145. [Epub ahead of print] No abstract available.

PMID:
29982526
17.

Association between smoking and risk of primary sclerosing cholangitis: A systematic review and meta-analysis.

Wijarnpreecha K, Panjawatanan P, Mousa OY, Cheungpasitporn W, Pungpapong S, Ungprasert P.

United European Gastroenterol J. 2018 May;6(4):500-508. doi: 10.1177/2050640618761703. Epub 2018 Feb 21.

18.

Tumor Necrosis Factor Alpha Inhibition for Inflammatory Bowel Disease after Liver Transplant for Primary Sclerosing Cholangitis.

Parekh R, Abdulhamid A, Trudeau S, Kaur N.

Case Rep Gastrointest Med. 2018 May 15;2018:1015408. doi: 10.1155/2018/1015408. eCollection 2018.

19.

Aberrant expression of redox regulatory proteins in patients with concomitant primary Sclerosing cholangitis/inflammatory bowel disease.

Petersen DR, Orlicky DJ, Roede JR, Shearn CT.

Exp Mol Pathol. 2018 Aug;105(1):32-36. doi: 10.1016/j.yexmp.2018.05.012. Epub 2018 May 29.

PMID:
29852184
20.

Effects of vedolizumab, adalimumab and infliximab on biliary inflammation in individuals with primary sclerosing cholangitis and inflammatory bowel disease.

Tse CS, Loftus EV Jr, Raffals LE, Gossard AA, Lightner AL.

Aliment Pharmacol Ther. 2018 Jul;48(2):190-195. doi: 10.1111/apt.14829. Epub 2018 May 28.

PMID:
29808485

Supplemental Content

Loading ...
Support Center